US4853221A
(en)
|
1980-11-13 |
1989-08-01 |
Warner-Lambert Company |
Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
|
US4801575A
(en)
|
1986-07-30 |
1989-01-31 |
The Regents Of The University Of California |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
US5294430A
(en)
|
1988-09-12 |
1994-03-15 |
University Of Rochester |
Use of dithiocarbamates to treat myelosuppression
|
US5035878A
(en)
|
1988-09-12 |
1991-07-30 |
University Of Rochester |
Use of dithiocarbamates to counteract myelosuppression
|
US5542935A
(en)
|
1989-12-22 |
1996-08-06 |
Imarx Pharmaceutical Corp. |
Therapeutic delivery systems related applications
|
US5597798A
(en)
|
1990-03-05 |
1997-01-28 |
The Regents Of The University Of California |
Taxol and epidermal growth factor used to enhance treatment of ovarian cancer
|
EP0572549B1
(en)
|
1991-02-21 |
2002-11-20 |
Smithkline Beecham Corporation |
Use of topotecan in the treatment of non-small cell lung carcinoma
|
US6287792B1
(en)
|
1991-06-17 |
2001-09-11 |
The Regents Of The University Of California |
Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
|
US5795870A
(en)
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
KR970702725A
(en)
|
1994-04-26 |
1997-06-10 |
노부히로 나리따 |
Medical Composition as a Remedy for Nonsmall Cell Lung Cancer
|
US6011069A
(en)
|
1995-12-26 |
2000-01-04 |
Nisshin Flour Milling Co., Ltd. |
Multidrug resistance inhibitors
|
US5998402A
(en)
|
1996-04-19 |
1999-12-07 |
American Home Products Corporation |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
|
WO1998055650A1
(en)
|
1997-06-04 |
1998-12-10 |
Rijksuniversiteit Te Leiden |
A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
|
US6335156B1
(en)
|
1997-12-18 |
2002-01-01 |
The Johns Hopkins University School Of Medicine |
14-3-3σ arrests the cell cycle
|
CA2319495A1
(en)
|
1998-06-08 |
1999-12-16 |
Advanced Medicine, Inc. |
Multibinding inhibitors of microsomal triglyceride transferase protein
|
ATE315392T1
(en)
|
1998-07-09 |
2006-02-15 |
Francis A Nardella |
COMPOSITIONS FOR TREATING CHRONIC LYMPHATIC LEUKEMIA
|
AU6607100A
(en)
|
1999-07-23 |
2001-02-13 |
Regents Of The University Of California, The |
Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
|
US6635677B2
(en)
|
1999-08-13 |
2003-10-21 |
Case Western Reserve University |
Methoxyamine combinations in the treatment of cancer
|
US6372250B1
(en)
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
US20020037328A1
(en)
*
|
2000-06-01 |
2002-03-28 |
Brown Dennis M. |
Hexitol compositions and uses thereof
|
GB0014820D0
(en)
|
2000-06-16 |
2000-08-09 |
Medical Res Council |
Methods and materials relating to plasmid vectors
|
ITMI20002358A1
(en)
|
2000-10-31 |
2002-05-01 |
Flavio Moroni |
TIENO DERIVATIVES, 2, 3-C | ISOCHINOLIN-3-ONE AS INHIBITORS OF POLY (DP-RIBOSE) POLYMERASE
|
US7619005B2
(en)
|
2000-11-01 |
2009-11-17 |
Cognition Pharmaceuticals Llc |
Methods for treating cognitive impairment in humans with Multiple Sclerosis
|
WO2003000012A2
(en)
|
2001-06-21 |
2003-01-03 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
|
EP1585817B1
(en)
|
2002-02-20 |
2009-09-02 |
The General Hospital Corporation |
Conjugates comprising a biodegradable polymer and uses therefor
|
CA2477953A1
(en)
|
2002-03-01 |
2003-09-12 |
Roger Williams Hospital |
Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
|
AU2003223529A1
(en)
|
2002-04-11 |
2003-10-27 |
Zymogenetics, Inc. |
Use of interleukin-19 to treat ovarian cancer
|
CA2480176A1
(en)
|
2002-04-11 |
2003-10-23 |
Zymogenetics, Inc. |
Use of interleukin-24 to treat ovarian cancer
|
US7101576B2
(en)
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7388079B2
(en)
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
US20060058217A1
(en)
|
2003-01-21 |
2006-03-16 |
White Hillary D |
Compositions and methods for treatment of ovarian cancer
|
NZ567952A
(en)
|
2003-03-24 |
2009-12-24 |
Sequoia Pharmaceuticals Inc |
Long acting biologically active conjugates
|
ZA200507752B
(en)
|
2003-03-28 |
2007-01-31 |
Threshold Pharmaceuticals Inc |
Compositions and methods for treating cancer
|
HUE059464T2
(en)
|
2003-04-11 |
2022-11-28 |
Ptc Therapeutics Inc |
1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
|
EP1663202A1
(en)
|
2003-09-04 |
2006-06-07 |
Aventis Pharmaceuticals, Inc. |
Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
|
US7446122B2
(en)
|
2003-10-02 |
2008-11-04 |
Cephalon, Inc. |
Substituted indole derivatives
|
HUP0303313A2
(en)
|
2003-10-09 |
2005-07-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
Transdermal pharmaceutical compositions
|
AU2004289539C1
(en)
|
2003-11-14 |
2012-06-07 |
Lorus Therapeutics Inc. |
Aryl imidazoles and their use as anti-cancer agents
|
JP4856623B2
(en)
|
2004-03-11 |
2012-01-18 |
フォーエスシー アクチエンゲゼルシャフト |
Novel N-sulfonylpyrrole derivatives
|
WO2005099824A1
(en)
|
2004-03-30 |
2005-10-27 |
Synta Pharmaceuticals, Corp. |
1-glyoxylamide indolizines for treating lung and ovarian cancer
|
WO2005098446A2
(en)
|
2004-03-31 |
2005-10-20 |
The Johns Hopkins University |
Biomarkers for ovarian cancer
|
US8957056B2
(en)
|
2004-05-25 |
2015-02-17 |
Sloan-Kettering Instiute For Cancer Research |
Migrastatin analogs in the treatment of cancer
|
DE602005026391D1
(en)
|
2004-06-30 |
2011-03-31 |
Janssen Pharmaceutica Nv |
CHINAZOLINONE DERIVATIVES AS PARP HEMMER
|
EP1864998B2
(en)
|
2004-07-22 |
2022-06-22 |
Erasmus University Medical Center Rotterdam |
Binding molecules
|
AU2005277648B2
(en)
|
2004-08-20 |
2011-12-22 |
Buck Institute For Age Research |
Small molecules that replace or agonize p53 function
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
US8080675B2
(en)
|
2004-09-21 |
2011-12-20 |
Marshall Edwards, Inc. |
Chroman derivatives, medicaments and use in therapy
|
CA2588389A1
(en)
|
2004-11-23 |
2006-06-22 |
Ptc Therapeutics, Inc. |
Substituted phenols as active agents inhibiting vegf production
|
DK1827437T3
(en)
|
2004-12-15 |
2012-02-13 |
Sigma Tau Ind Farmaceuti |
Combinations of therapeutic agents for cancer treatment
|
WO2006078711A2
(en)
|
2005-01-19 |
2006-07-27 |
Mgi Gp, Inc. |
Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
|
US8404829B2
(en)
|
2005-01-25 |
2013-03-26 |
The Regents Of The University Of California |
Predictive and therapeutic markers in ovarian cancer
|
EP1702989A1
(en)
|
2005-03-16 |
2006-09-20 |
Fundacion para la Investigacion Clinica y Molecular del Cancer de Pulmon |
Method of predicting the clinical response to cisplatin or carboplatin chemotherapeutic treatment
|
US7728026B2
(en)
|
2005-04-11 |
2010-06-01 |
Abbott Laboratories, Inc. |
2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
|
BRPI0608096A2
(en)
|
2005-04-26 |
2009-11-10 |
Pfizer |
p-cadherin antibodies
|
AR053272A1
(en)
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
DETERMINATION OF RESPONSIVES TO CHEMOTHERAPY
|
BRPI0612138B8
(en)
|
2005-06-15 |
2021-05-25 |
Cardiome Pharma Corp |
aminocyclohexyl ether compounds and method of making them
|
EP1910821B1
(en)
|
2005-06-24 |
2013-02-20 |
Ciphergen Biosystems, Inc. |
Biomarkers for ovarian cancer
|
EP1924568A1
(en)
*
|
2005-07-15 |
2008-05-28 |
Schering Corporation |
Quinazoline derivatives useful in cancer treatment
|
WO2007013946A2
(en)
|
2005-07-20 |
2007-02-01 |
University Of South Florida |
Method of predicting responsiveness to chemotherapy and selecting treatments
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
AU2006279794B2
(en)
|
2005-08-12 |
2011-04-07 |
Synta Pharmaceuticals Corp. |
Pyrazole compounds that modulate HSP90 activity
|
US7507536B2
(en)
|
2005-10-07 |
2009-03-24 |
The Johns Hopkins University |
Methylation markers for diagnosis and treatment of ovarian cancer
|
US8124095B2
(en)
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
EP1938823A1
(en)
|
2005-10-19 |
2008-07-02 |
Chugai Seiyaku Kabushiki Kaisha |
Agent for preventing or treating pancreas cancer, ovary cancer or liver cancer containing novel water-soluble prodrug
|
US20090099102A1
(en)
|
2005-10-27 |
2009-04-16 |
The Brigham And Women's Hospital, Inc. |
Ginkgolides in the Treatment and Prevention of Ovarian Cancer
|
CA2833706C
(en)
|
2005-11-11 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
EP1951283B1
(en)
|
2005-11-16 |
2010-07-14 |
Pantarhei Bioscience B.V. |
Pharmaceutical composition for treating or preventing ovarian cancer
|
US8450351B2
(en)
|
2005-12-20 |
2013-05-28 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
WO2007070984A1
(en)
|
2005-12-23 |
2007-06-28 |
Ecobiotics Limited |
Spiroketals
|
EP1986625B1
(en)
|
2006-02-10 |
2012-08-01 |
Ramot at Tel-Aviv University Ltd. |
Treatment of ovarian cancer
|
KR101549364B1
(en)
|
2006-03-17 |
2015-09-01 |
암비트 바이오사이언시즈 코포레이션 |
Imidazolothiazole compounds for the treatment of disease
|
AR060631A1
(en)
|
2006-04-26 |
2008-07-02 |
Piramed Ltd |
DERIVATIVES OF PIRIMIDINE AND ITS USE AS INHIBITORS OF PHOSFATIDYLNOSITOL 3-QUINASE (PI3K)
|
IL282783B2
(en)
|
2006-05-18 |
2023-09-01 |
Caris Mpi Inc |
System and method for determining individualized medical intervention for a disease state
|
US8768629B2
(en)
|
2009-02-11 |
2014-07-01 |
Caris Mpi, Inc. |
Molecular profiling of tumors
|
CA2653217A1
(en)
|
2006-05-25 |
2007-12-06 |
Synta Pharmaceuticals Corp. |
Method for treating proliferative disorders associated with protooncogene products
|
CA2653222A1
(en)
|
2006-05-25 |
2007-12-06 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
CA2655561C
(en)
|
2006-06-20 |
2014-10-21 |
Abbott Laboratories |
Pyrazoloquinazolinones as parp inhibitors
|
DK2061765T3
(en)
|
2006-09-01 |
2015-01-26 |
Senhwa Biosciences Inc |
Serine-threonine protein kinase AND PARP-MODULATOR
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
JP5721949B2
(en)
|
2006-10-12 |
2015-05-20 |
アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited |
Compound drug
|
UY30639A1
(en)
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS
|
EP2815750A1
(en)
|
2006-12-21 |
2014-12-24 |
Vertex Pharmaceuticals Incorporated |
5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
|
UY30892A1
(en)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
AKT ACTIVITY INHIBITORS
|
WO2008098139A2
(en)
|
2007-02-07 |
2008-08-14 |
The Regents Of The University Of Colorado |
Axl tyrosine kinase inhibitors and methods of making and using the same
|
PL2716301T3
(en)
|
2007-02-16 |
2017-10-31 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
CA2677046A1
(en)
|
2007-02-28 |
2008-09-04 |
Inotek Pharmaceuticals Corporation |
Indenoisoquinolinone analogs and methods of use thereof
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
US8299256B2
(en)
|
2007-03-08 |
2012-10-30 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as PARP and TANK inhibitors
|
US8030060B2
(en)
|
2007-03-22 |
2011-10-04 |
West Virginia University |
Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
|
AR065948A1
(en)
|
2007-04-06 |
2009-07-15 |
Neurocrine Biosciences Inc |
GONADOTROPINE LIBERATING HORMONE RECEIVER ANTAGONISTS AND PROCEDURES RELATED TO THEMSELVES
|
TWI448284B
(en)
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
Dual-acting antihypertensive agents
|
JP2008295328A
(en)
|
2007-05-30 |
2008-12-11 |
Fujifilm Corp |
Method for detecting ovarian cancer, and method for suppressing the same
|
CN101678019B
(en)
|
2007-06-08 |
2016-03-30 |
詹森药业有限公司 |
Piperidine/piperazine derivatives
|
EP2637020A3
(en)
|
2007-06-29 |
2014-01-08 |
Correlogic Systems Inc. |
Predictive markers for ovarian cancer
|
WO2009016565A1
(en)
|
2007-07-27 |
2009-02-05 |
Piramal Life Sciences Limited |
Tricyclic compounds for the treatment of inflammatory disorders
|
SA08290475B1
(en)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2S,3R)-N-(2-((3-Pyridinyl)Methyl)-1-Azabicyclo[2.2.2]Oct-3-yl)Benzofuran-2-Carboxamide, Novel Salt forms, and Methods of Use Thereof
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
AU2008287831B2
(en)
|
2007-08-10 |
2013-05-23 |
Mitsubishi Tanabe Pharma Corporation |
Novel salt of isoquinoline compound and crystal thereof
|
CN101802226A
(en)
|
2007-09-17 |
2010-08-11 |
皇家飞利浦电子股份有限公司 |
The method of the analysis of ovarian cancer disorders
|
RU2485122C2
(en)
|
2007-10-03 |
2013-06-20 |
Эйсэй Инк. |
Parp-inhibiting compounds and compositions, and methods for using them
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain Compounds, Compositions and Methods
|
WO2009058102A1
(en)
|
2007-11-02 |
2009-05-07 |
Agency For Science, Technology And Research |
Methods and compounds for preventing and treating a tumour
|
IL187247A0
(en)
|
2007-11-08 |
2008-12-29 |
Hadasit Med Res Service |
Novel synthetic analogs of sphingolipids
|
EP2217244A4
(en)
|
2007-11-12 |
2011-08-31 |
Bipar Sciences Inc |
Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
|
US20090170842A1
(en)
|
2007-11-14 |
2009-07-02 |
University Of Kansas |
Brca1-based breast or ovarian cancer prevention agents and methods of use
|
RU2490265C2
(en)
|
2007-11-15 |
2013-08-20 |
Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти С.П.А. |
Pyridazinone derivatives as parp inhibitors
|
WO2009065230A1
(en)
|
2007-11-23 |
2009-05-28 |
British Columbia Cancer Agency Branch |
Methods for detecting lung cancer and monitoring treatment response
|
US8476420B2
(en)
|
2007-12-05 |
2013-07-02 |
The Wistar Institute Of Anatomy And Biology |
Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
|
WO2009071660A1
(en)
|
2007-12-06 |
2009-06-11 |
Novartis Forschungsstiftung, Zweigniederlassung |
Use of protease nexin 1 inhibitors to reduce metastasis
|
US8741889B2
(en)
|
2008-01-11 |
2014-06-03 |
Hoffmann-La Roche Inc |
Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
|
WO2009097446A1
(en)
|
2008-01-30 |
2009-08-06 |
Genentech, Inc. |
Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
|
WO2009099561A2
(en)
|
2008-01-31 |
2009-08-13 |
The Brigham And Womens' Hospital, Inc. |
Urinary ca125 peptides as biomarkers of ovarian cancer
|
CN101998959B
(en)
|
2008-02-06 |
2013-08-28 |
生物马林药物股份有限公司 |
Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP)
|
CN104474529A
(en)
|
2008-02-08 |
2015-04-01 |
爱勒让治疗公司 |
Therapeutic peptidomimetic macrocycles
|
US8828657B2
(en)
|
2008-02-14 |
2014-09-09 |
Decode Genetics Ehf. |
Susceptibility variants for lung cancer
|
US8541433B2
(en)
|
2008-02-20 |
2013-09-24 |
Actelion Pharmaceuticals, Ltd. |
Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
|
FR2928151B1
(en)
|
2008-03-03 |
2010-12-31 |
Sanofi Aventis |
N-HETEROCYCLIC PLATINUM-CARBENE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
|
MX2010010172A
(en)
|
2008-03-17 |
2010-11-25 |
Ambit Biosciences Corp |
Quinazoline derivatives as raf kinase modulators and methods of use thereof.
|
US8476026B2
(en)
|
2008-04-01 |
2013-07-02 |
The Brigham And Women's Hospital, Inc. |
Biomarkers of ovarian cancer
|
MX2010011258A
(en)
|
2008-04-14 |
2011-06-20 |
Univ Texas |
Small molecule inhibitors of the pleckstrin homology domain and methods for using same.
|
ES2584932T3
(en)
|
2008-04-16 |
2016-09-30 |
Assistance Publique Hôpitaux De Paris |
Methods for treatment, prognostic evaluation and staging of non-small cell lung cancer
|
CL2009001152A1
(en)
|
2008-05-13 |
2009-10-16 |
Array Biopharma Inc |
Compounds derived from n- (4- (nitrogen cycloalkyl-1-yl) -1h-pyrrolo [2,3-b] pyridin-3-yl) amide, kinase inhibitors; Preparation process; pharmaceutical composition; and its use for the treatment of a proliferative disease.
|
JP5583117B2
(en)
|
2008-05-14 |
2014-09-03 |
ユニバーシティー ヘルス ネットワーク |
Prognostic and predictive gene signatures for non-small cell lung cancer and adjuvant chemotherapy
|
CA2725754C
(en)
|
2008-06-11 |
2017-05-23 |
Hazel Joan Dyke |
Diazacarbazoles and methods of use
|
ES2399319T3
(en)
|
2008-07-09 |
2013-03-27 |
Rigel Pharmaceuticals, Inc. |
Bicyclic heteroaryl substituted triazoles containing bridges useful as AXL inhibitors
|
US8946239B2
(en)
|
2008-07-10 |
2015-02-03 |
Duquesne University Of The Holy Spirit |
Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
|
WO2010006292A1
(en)
|
2008-07-11 |
2010-01-14 |
Neumedics |
Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
|
SG193842A1
(en)
|
2008-08-06 |
2013-10-30 |
Biomarin Pharm Inc |
Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
|
WO2010017545A2
(en)
|
2008-08-08 |
2010-02-11 |
Synta Pharamceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
EA022884B1
(en)
|
2008-08-15 |
2016-03-31 |
Мерримак Фармасьютикалз, Инк. |
METHOD FOR TREATING NEOPLASTIC TUMOR USING ANTI-ErbB3 ANTIBODY
|
WO2010020675A1
(en)
|
2008-08-22 |
2010-02-25 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
EP2166008A1
(en)
|
2008-09-23 |
2010-03-24 |
Genkyo Tex Sa |
Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
|
KR100961410B1
(en)
|
2008-10-14 |
2010-06-09 |
(주)네오팜 |
Heterocyclic compounds as protein kinases inhibitors
|
GB0819095D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
WO2010048330A1
(en)
|
2008-10-21 |
2010-04-29 |
Threshold Pharmaceuticals, Inc. |
Treatment of cancer using hypoxia activated prodrugs
|
US8946289B2
(en)
|
2008-11-19 |
2015-02-03 |
Duke University |
Manassatin compounds and methods of making and using the same
|
MX2011005526A
(en)
|
2008-11-26 |
2011-06-06 |
Pfizer |
3-aminocyclopentanecarboxamides as chemokine receptor modulators.
|
US20100160322A1
(en)
|
2008-12-04 |
2010-06-24 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8058075B2
(en)
|
2008-12-10 |
2011-11-15 |
University Of Utah Research Foundation |
Molecular fluorescence sensor for highly sensitive and selective detection of mercury
|
ES2490613T3
(en)
|
2008-12-22 |
2014-09-04 |
F. Hoffmann-La Roche Ag |
ARMET as a cancer marker
|
SG172958A1
(en)
|
2009-01-23 |
2011-08-29 |
Takeda Pharmaceutical |
Poly (adp-ribose) polymerase (parp) inhibitors
|
CA2789365A1
(en)
|
2009-02-10 |
2010-08-19 |
Celgene International Sarl |
Methods for treating non-small cell lung cancer using 5-azacytidine
|
US8648046B2
(en)
|
2009-02-26 |
2014-02-11 |
Oncolix, Inc. |
Compositions and methods for visualizing and eliminating cancer stem cells
|
MY159327A
(en)
|
2009-02-27 |
2016-12-25 |
Ambit Biosciences Corp |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
US8969001B2
(en)
|
2009-03-12 |
2015-03-03 |
Rush University Medical Center |
Materials and methods for predicting recurrence of non-small cell lung cancer
|
CN101869558A
(en)
*
|
2009-04-22 |
2010-10-27 |
北京大学 |
Anti-angiogenesis and anti-metastasis effect of diacetyldianhydrogalactitol
|
PT104607B
(en)
|
2009-05-20 |
2012-03-23 |
Univ De Coimbra |
USEFUL TRITERPENOID DERIVATIVES AS ANTIPROLIFERATIVE AGENTS
|
EP3045457B1
(en)
|
2009-06-15 |
2018-05-09 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
|
US8980268B2
(en)
|
2009-07-29 |
2015-03-17 |
Regeneron Pharamceuticals, Inc. |
Methods for treating cancer by administering an anti-Ang-2 antibody
|
WO2011014681A1
(en)
|
2009-07-30 |
2011-02-03 |
Takeda Pharmaceutical Company Limited |
Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS
|
EP2460005A4
(en)
|
2009-07-31 |
2012-11-21 |
Translational Genomics Res Inst |
Methods of assessing a risk of cancer progression
|
WO2011024873A1
(en)
|
2009-08-26 |
2011-03-03 |
武田薬品工業株式会社 |
Fused heterocyclic ring derivative and use thereof
|
US20130203861A1
(en)
|
2009-09-09 |
2013-08-08 |
Golden Biotechnology Corporation |
Methods and compositions for treating ovarian cancer
|
US20120183546A1
(en)
|
2009-09-23 |
2012-07-19 |
Amgen Inc. |
Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
|
ES2558742T3
(en)
|
2009-09-28 |
2016-02-08 |
F. Hoffmann-La Roche Ag |
Benzoxepine PI3K inhibitor compounds and methods of use
|
MX2012004064A
(en)
|
2009-10-08 |
2012-06-08 |
Sanford Burnham Med Res Inst |
Apogossypolone derivatives as anticancer agents.
|
EP2486002B1
(en)
|
2009-10-09 |
2019-03-27 |
Oryzon Genomics, S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
WO2011088192A1
(en)
|
2010-01-13 |
2011-07-21 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
SA111320200B1
(en)
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
|
JP5972176B2
(en)
|
2010-02-23 |
2016-08-17 |
サノフイ |
Anti-alpha2 integrin antibodies and uses thereof
|
EP2548017A2
(en)
|
2010-03-15 |
2013-01-23 |
Genus Oncology, Llc |
Small molecule inhibitors of muc1 and methods of identifying the same
|
EP2403855B1
(en)
|
2010-03-22 |
2013-05-01 |
Council of Scientific & Industrial Research |
Carbazole linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
|
PL2563803T3
(en)
|
2010-04-27 |
2016-08-31 |
Pharma Mar Sa |
Anticancer steroidal lactones unsaturated in position 7(8)
|
US8980933B2
(en)
|
2010-05-05 |
2015-03-17 |
Universitat Bayreuth |
Combretastatin analogs for use in the treatment of cancer
|
CN103003424B
(en)
|
2010-05-18 |
2015-05-13 |
株式会社医学生物学研究所 |
Antibody capable of binding to transforming growth factor alpha and having antiproliferative activity on cancer having Ras gene mutation
|
MX365251B
(en)
|
2010-05-20 |
2019-05-28 |
Array Biopharma Inc |
Macrocyclic compounds as trk kinase inhibitors.
|
BR112012033253A2
(en)
|
2010-06-23 |
2016-11-22 |
Hanmi Science Co Ltd |
novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
|
WO2012006563A2
(en)
|
2010-07-08 |
2012-01-12 |
The Administrators Of The Tulane Educational Fund |
Novel daidzein analogs as treatment for cancer
|
ES2552841T3
(en)
|
2010-07-12 |
2015-12-02 |
Bayer Intellectual Property Gmbh |
Imidazo [1,2-a] pyrimidines and substituted -pyridines
|
GB201012105D0
(en)
|
2010-07-19 |
2010-09-01 |
Domainex Ltd |
Novel pyrimidine compounds
|
US20120171694A1
(en)
|
2010-07-30 |
2012-07-05 |
Vermillion, Inc. |
Predictive markers and biomarker panels for ovarian cancer
|
JP5512894B2
(en)
|
2010-08-05 |
2014-06-04 |
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション |
2-Substituted-8-alkyl-7-oxo-7,8-dihydropyrido [2,3d] pyrimidine-6-carbonitrile and uses thereof
|
CN103476250A
(en)
*
|
2010-08-18 |
2013-12-25 |
德玛医药 |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
|
WO2012027564A1
(en)
|
2010-08-26 |
2012-03-01 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
JP5842004B2
(en)
|
2010-09-01 |
2016-01-13 |
ジーアイリード コネチカット インコーポレーテッドGilead Connecticut,Inc. |
Pyridazinone, its production method and its use
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
US8575191B2
(en)
|
2010-09-01 |
2013-11-05 |
Arqule, Inc. |
Methods for treatment of non-small cell lung cancer
|
WO2012037573A1
(en)
|
2010-09-17 |
2012-03-22 |
Indiana University Research And Technology Corporation |
Small molecule inhibitors of replication protein a that also act synergistically with cisplatin
|
US8927562B2
(en)
|
2010-09-28 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Fused tricyclic inhibitors of mammalian target of rapamycin
|
KR101497113B1
(en)
|
2010-10-20 |
2015-03-03 |
한국생명공학연구원 |
Aryloxyphenoxyacryl-based compounds having HIF-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient
|
BR112013009531A2
(en)
|
2010-11-11 |
2016-07-19 |
Redx Pharma Ltd |
drug derivatives
|
CN103403552B
(en)
|
2010-11-12 |
2016-01-06 |
恩多塞特公司 |
The method of Therapeutic cancer
|
AR083916A1
(en)
|
2010-11-18 |
2013-04-10 |
Takeda Pharmaceutical |
METHOD TO TREAT BREAST CANCER AND OVARIAN CANCER
|
EP2646430B1
(en)
|
2010-12-03 |
2016-09-21 |
Emory University |
Chemokine cxcr4 receptor modulators and uses related thereto
|
WO2012076942A1
(en)
|
2010-12-06 |
2012-06-14 |
Council Of Scientific & Industrial Research |
4-aza-2, 3-didehydropodophyllotoxin compounds and process for the preparation thereof
|
AR084312A1
(en)
|
2010-12-16 |
2013-05-08 |
Genentech Inc |
INHIBITING TRICICLIC COMPOUNDS OF THE PI3K AND PHARMACEUTICAL COMPOSITIONS
|
KR20140022786A
(en)
|
2010-12-17 |
2014-02-25 |
데스 알 리처드슨 |
Thiosemicarbazone compounds and use in the treatment of cancer
|
WO2012096832A2
(en)
|
2011-01-12 |
2012-07-19 |
Crystal Biopharmaceutical Llc |
Hdac inhibiting derivatives of camptothecin
|
CN103339134B
(en)
|
2011-01-26 |
2015-12-23 |
内尔维阿诺医学科学有限公司 |
Tricyclic azole derivative, their preparation method and they are as the application of kinase inhibitor
|
WO2012103456A2
(en)
|
2011-01-27 |
2012-08-02 |
Board Of Regents, The University Of Texas System |
Polycyclic beta lactam derivatives for the treatment of cancer
|
AP2013007043A0
(en)
|
2011-01-31 |
2013-08-31 |
Novartis Ag |
Novel heterocyclic derivatives
|
WO2012116328A2
(en)
|
2011-02-24 |
2012-08-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bad phosphorylation determines ovarian cancer chemo-sensitivity and patient survival
|
WO2012115820A2
(en)
|
2011-02-24 |
2012-08-30 |
Vermillion, Inc. |
Biomarker panels, diagnostic methods and test kits for ovarian cancer
|
RU2598849C2
(en)
|
2011-02-24 |
2016-09-27 |
Цзянсу Хэнсох Фармасьютикал Ко., Лтд. |
Phosphorus containing compounds as protein kinase inhibitors
|
WO2012118812A2
(en)
|
2011-02-28 |
2012-09-07 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
SG192841A1
(en)
|
2011-03-01 |
2013-09-30 |
Nucana Biomed Ltd |
Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
|
WO2012119113A2
(en)
|
2011-03-02 |
2012-09-07 |
Nestec Sa |
Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
|
US8987412B2
(en)
|
2011-03-04 |
2015-03-24 |
New York University |
Hydrogen bond surrogate macrocycles as modulators of Ras
|
US8748470B2
(en)
|
2011-03-17 |
2014-06-10 |
The University Of Chicago |
Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
|
US20140357605A1
(en)
|
2012-03-22 |
2014-12-04 |
Bristol-Myers Squibb Company |
Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
|
US20120269827A1
(en)
|
2011-04-01 |
2012-10-25 |
Immunogen, Inc. |
Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube Cancer
|
WO2012138678A1
(en)
|
2011-04-04 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
Gamma secretase inhibitors
|
JP6046710B2
(en)
|
2011-06-24 |
2016-12-21 |
アーキュール,インコーポレイティド |
Substituted imidazopyridinyl-aminopyridine compounds
|
CA2881993C
(en)
|
2011-07-27 |
2017-05-09 |
Astrazeneca Ab |
Substituted 4-methoxy-n3-(pyrimidin-2-yl)benzene-1,3-diamine compounds, and salts thereof
|
US9499530B2
(en)
|
2011-08-01 |
2016-11-22 |
Hangzhou Minsheng Institutes For Pharma Research |
Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
|
EP2739618B1
(en)
|
2011-08-04 |
2015-09-16 |
Array Biopharma, Inc. |
Quinazoline compounds as serine/threonine kinase inhibitors
|
US9045450B2
(en)
|
2011-08-10 |
2015-06-02 |
Zhen Yang |
Method for chemical synthesis of antrocin and use thereof for suppressing non-small cell lung cancer
|
DE102011112978A1
(en)
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
benzonitrile derivatives
|
EA023171B1
(en)
|
2011-09-19 |
2016-04-29 |
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. |
Thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments
|
WO2013043255A1
(en)
|
2011-09-21 |
2013-03-28 |
University Of South Alabama |
Methods and compositions for the treatment of ovarian cancer
|
WO2013041042A1
(en)
|
2011-09-22 |
2013-03-28 |
Merck Sharp & Dohme Corp. |
Pyrazole carboxamides as janus kinase inhibitors
|
PE20141581A1
(en)
|
2011-09-27 |
2014-11-14 |
Novartis Ag |
3-PIRMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF MUTANT HDI
|
HUE031445T2
(en)
|
2011-09-28 |
2017-07-28 |
Euro Celtique Sa |
Nitrogen mustard derivatives
|
CN104039797B
(en)
|
2011-10-12 |
2016-06-01 |
南京奥昭生物科技有限公司 |
As the heterocyclic molecular of cell death inducer
|
CN103958508B
(en)
|
2011-10-14 |
2019-02-12 |
艾伯维公司 |
For treating cancer and the immune cell death inducer with autoimmune disease
|
US20140357594A1
(en)
|
2011-10-24 |
2014-12-04 |
Glaxosmithkline Intellectual Property (No.2) Limited |
New compounds
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
BR112014010699B1
(en)
|
2011-11-03 |
2020-12-15 |
Millennium Pharmaceuticals, Inc |
USE OF A NAE INHIBITOR WITH A HYPOMETHILLATION AGENT TO TREAT HEMATOLOGICAL MALIGNITY AND KIT
|
PE20141686A1
(en)
|
2011-11-03 |
2014-11-08 |
Hoffmann La Roche |
PIPERAZINE COMPOUNDS RENTED AS BTK ACTIVITY INHIBITORS
|
JP2015501792A
(en)
|
2011-11-10 |
2015-01-19 |
メモリアル スローン−ケタリング キャンサー センター |
Treatment of ovarian cancer with benzylidene benzohydrazide
|
CN104185631A
(en)
|
2011-11-10 |
2014-12-03 |
纪念斯隆-凯特琳癌症中心 |
Treatment of ovarian cancer with 2-amino-4h-naphtho[1,2-b]pyran-3-carbonitriles
|
US9844529B2
(en)
|
2011-11-11 |
2017-12-19 |
Eli Lilly And Company |
Combination therapy for ovarian cancer
|
BR112014012407A2
(en)
|
2011-11-22 |
2017-06-06 |
Deciphera Pharmaceuticals Llc |
pyridone amides and analogs exhibiting anti-cancer and anti-proliferative properties
|
CN104066435A
(en)
|
2011-12-21 |
2014-09-24 |
纽约大学 |
Proteolytically resistant hydrogen bond surrogate helices
|
CN104066735B
(en)
|
2012-01-10 |
2016-08-31 |
拜耳知识产权有限责任公司 |
Substituted Imidazopyrazines as AKT inhibitors of kinases
|
EP2804850B1
(en)
|
2012-01-19 |
2018-08-29 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
MX367614B
(en)
*
|
2012-01-20 |
2019-08-28 |
Del Mar Pharmaceuticals |
Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma.
|
PL2810937T3
(en)
|
2012-01-31 |
2017-07-31 |
Daiichi Sankyo Company, Limited |
Pyridone derivative
|
AR092790A1
(en)
|
2012-02-01 |
2015-05-06 |
Euro Celtique Sa |
BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID
|
SG10201507865QA
(en)
|
2012-03-06 |
2015-10-29 |
Cephalon Inc |
Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
|
US9266828B2
(en)
|
2012-03-16 |
2016-02-23 |
Sanford-Burnham Medical Research Institute |
Inhibitors of Furin and other pro-protein convertases
|
MX359770B
(en)
|
2012-03-20 |
2018-10-10 |
Novartis Ag Star |
Combination therapy of a mek inhibitor and igf1r inhibitor.
|
CA2865719C
(en)
|
2012-03-30 |
2020-09-22 |
Rhizen Pharmaceuticals Sa |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
|
US10280168B2
(en)
|
2012-03-30 |
2019-05-07 |
Agency For Science, Technology And Research |
Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
|
US9809858B2
(en)
|
2012-04-05 |
2017-11-07 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
O-glycan pathway ovarian cancer signature
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
CA2873097A1
(en)
|
2012-05-11 |
2013-11-14 |
Todd M. Hansen |
Pyridazine and pyridine derivatives as nampt inhibitors
|
WO2013181462A1
(en)
|
2012-05-31 |
2013-12-05 |
Amgen Inc. |
Use of amg 900 for the treatment of cancer
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
US8980934B2
(en)
|
2012-06-22 |
2015-03-17 |
University Health Network |
Kinase inhibitors and method of treating cancer with same
|
CN104797267A
(en)
*
|
2012-06-26 |
2015-07-22 |
德玛医药 |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
WO2014009319A1
(en)
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
Indolinone derivatives anticancer compounds
|
WO2014078295A1
(en)
|
2012-11-13 |
2014-05-22 |
BoYen Therapeutics, Inc. |
Gemcitabine prodrugs and uses thereof
|
TW201438736A
(en)
|
2012-11-14 |
2014-10-16 |
Regeneron Pharma |
Methods of treating ovarian cancer with Dll4 antagonists
|
US8946246B2
(en)
|
2012-11-16 |
2015-02-03 |
New Mexico Technical Research Foundation |
Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same
|
US8987461B2
(en)
|
2012-12-06 |
2015-03-24 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
RU2690663C2
(en)
|
2012-12-20 |
2019-06-05 |
Мерк Шарп И Доум Корп. |
Substituted imidazopyridines as hdm2 inhibitors
|
WO2014100818A1
(en)
|
2012-12-21 |
2014-06-26 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
US8940726B2
(en)
|
2012-12-21 |
2015-01-27 |
Epizyme, Inc. |
PRMT5 inhibitors and uses thereof
|
RS56169B1
(en)
|
2013-02-14 |
2017-11-30 |
Bristol Myers Squibb Co |
Tubulysin compounds, methods of making and use
|
MX2015012158A
(en)
|
2013-03-11 |
2015-12-01 |
Abbvie Inc |
Fused tetracyclic bromodomain inhibitors.
|
AU2014244263A1
(en)
|
2013-03-13 |
2015-08-13 |
Abbvie Inc. |
CDK9 kinase inhibitors
|
JP2016512816A
(en)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
EP2970289A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
US10413538B2
(en)
|
2013-05-08 |
2019-09-17 |
Bionumerik Pharmaceuticals, Inc. |
Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer
|
US20140371158A1
(en)
|
2013-06-14 |
2014-12-18 |
Georgia Regents University |
Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway
|
AU2014100435A4
(en)
|
2013-06-17 |
2014-05-29 |
Macau University Of Science And Technology |
A novel treatment of Gefitinib-resistant non-small-cell lung cancer
|
KR101815360B1
(en)
|
2013-07-03 |
2018-01-04 |
에프. 호프만-라 로슈 아게 |
Heteroaryl pyridone and aza-pyridone amide compounds
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
US9278978B2
(en)
|
2013-08-23 |
2016-03-08 |
Boehringer Ingelheim International Gmbh |
6-Alkynyl Pyridine
|
US9249151B2
(en)
|
2013-08-23 |
2016-02-02 |
Boehringer Ingelheim International Gmbh |
Bis-amido pyridines
|
US20150065526A1
(en)
|
2013-09-05 |
2015-03-05 |
Emory University |
Overcoming acquired resistance to chemotherapy treatments through suppression of stat3
|
US8927717B1
(en)
|
2014-02-14 |
2015-01-06 |
National Defense Medical Center |
Thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof
|